Brian Lo, MD
Internal Medicine · Irvine, CANPI 1073501565
Payments from drug & device makers
Across 91 payments — averaging $19.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$242
- Novo Nordisk$166
- AbbVie$158
- Amarin Pharma, Inc.$149
- Genentech USA, Inc.$125
- Grifols USA, LLC$115
- plus $802 from 21 others
What the payments were for
- Food & beverage$1,757100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 12 | $242 |
| Novo Nordisk | 10 | $166 |
| AbbVie(2 entities) | 8 | $158 |
| Amarin Pharma, Inc. | 10 | $149 |
| Genentech USA, Inc. | 1 | $125 |
| Grifols USA, LLC | 5 | $115 |
| Boehringer Ingelheim | 4 | $96 |
| IBSA Pharma Inc. | 4 | $76 |
| Kowa Pharmaceuticals America, Inc. | 4 | $69 |
| Jazz Pharmaceuticals Inc. | 4 | $59 |
| AstraZeneca | 3 | $54 |
| Merck | 3 | $52 |
| Pfizer | 3 | $52 |
| Sunovion Pharmaceuticals Inc. | 3 | $43 |
| Arbor Pharmaceuticals, Inc. | 2 | $36 |
| Johnson & Johnson | 2 | $35 |
| Corcept Therapeutics | 1 | $33 |
| GSK | 2 | $30 |
| Shire North American Group Inc | 2 | $26 |
| Mannkind Corporation | 1 | $24 |
| Nalpropion Pharmaceuticals LLC | 1 | $20 |
| Mylan Specialty L.p. | 1 | $19 |
| Linus Health, Inc. | 1 | $18 |
| Endo Pharmaceuticals Inc. | 1 | $16 |
| E.r. Squibb & Sons, L.L.C. | 1 | $16 |
| Esperion Therapeutics, Inc. | 1 | $15 |
| Bayer | 1 | $13 |
How this compares
$1,757 in reported general payments places this provider in the 80th percentile of 13,581 internal medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 11 | $303 |
| Gabapentin | 23 | $225 |
| Levothyroxine Sodium | 24 | $200 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 13 | $182 |
| Zolpidem Tartrate | 21 | $94 |
| Losartan Potassium | 24 | $91 |
| Duloxetine Hcl | 11 | $71 |
| Hydrochlorothiazide | 20 | $26 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Irvine
- Andrew ChengSouth San Francisco$55.1M
- Joel NeutelTustin$34.9M
- Donald BrandonSan Diego$34M
- William TownerLos Angeles$27.4M
- Rahul AggarwalSan Francisco$24M
- Masoud AzizadNorthridge$21.1M
- Helen StaceyWalnut Creek$20.4M
- Rohit Loombala Jolla$15.1M
- Zeid KayaliColton$14.2M
- Alexandra DrakakiSanta Monica$14.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.